Atrial Fibrillation Also called: AF, Afib

Clinical Trial Finder

Many patients with atrial fibrillation are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effect of Remote Ischemic Preconditioning on Electrophysiological and Biomolecular Parameters in Non-valvular Paroxysmal Atrial Fibrillation: RIPPAF Study

Condition:   Atrial Fibrillation
Intervention:   Procedure: Remote ischemic preconditioning (RIPC)
Sponsor:   Jedrzej Kosiuk
Not yet recruiting - verified May 2016

Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S

Condition:   Atrial Fibrillation
Interventions:   Drug: dabigatran;   Drug: rivaroxaban;   Drug: apixaban;   Drug: warfarin
Sponsor:   Bristol-Myers Squibb
Completed - verified May 2016

The Physiological Effects of Pacing on Catheter Ablation Procedures to Treat Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Procedure: Pace During 1st Half of Lesion;   Procedure: Pace During 2nd Half of Lesion
Sponsor:   New York University School of Medicine
Recruiting - verified May 2016

Study on Left Atrial Function of Atrial Fibrillation After Radiofrequency Ablation With Statin Therapy

Condition:   Atrial Fibrillation
Interventions:   Drug: atorvastatin group;   Drug: non-atorvastatin group
Sponsor:   xieruiqin
Recruiting - verified May 2016

Prospective Study Evaluating the Interest of Long-term Cardiac Recording in Cerebral Infarction

Condition:   Neuropathology
Intervention:   Device: Uses of SpiderFlash monitor
Sponsor:   Groupe Hospitalier Paris Saint Joseph
Recruiting - verified May 2016

Rivaroxaban vs Apixaban on Menstrual Blood Loss

Condition:   Venous Thromboembolism
Interventions:   Drug: apixaban;   Drug: rivaroxaban
Sponsors:   Indiana University;   Indiana University Health
Not yet recruiting - verified May 2016

Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   Svendborg Hospital;   Region of Southern Denmark;   Takeda
Active, not recruiting - verified May 2016

Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II

Conditions:   Atrial Fibrillation;   Stroke
Intervention:   Other: ECG screening (Zenicor-ECG) for atrial fibrillation
Sponsors:   Karolinska University Hospital;   Roche Pharma AG
Recruiting - verified May 2016

Omics Signature in the Diagnosis of Hypertension

Condition:   Hypertension
Intervention:   Other: omics
Sponsors:   Radboud University;   European Union
Not yet recruiting - verified April 2016

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Condition:   Post-Operative Atrial Fibrillation
Interventions:   Device: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems;   Drug: Anticoagulation Therapy (No AtriClip®)
Sponsor:   AtriCure, Inc.
Recruiting - verified May 2016

CFAEs Guided Ablation Versus PVI in Persistent AF

Condition:   Chronic Atrial Fibrillation
Interventions:   Procedure: CFAE guided ablation;   Procedure: PVI guided ablation
Sponsors:   Diagram B.V.;   Biosense Webster, Inc.
Recruiting - verified May 2016

Catheter Ablation vs. Medical Therapy in Congested Hearts With AF

Conditions:   Congestive Heart Failure;   Left Ventricular Failure;   Atrial Fibrillation
Intervention:   Device: Catheter Ablation
Sponsors:   Oussama Wazni;   Biosense Webster, Inc.;   The Cleveland Clinic
Not yet recruiting - verified May 2016

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Conditions:   Mild Tricuspid Regurgitation;   Moderate Tricuspid Regurgitation;   Tricuspid Regurgitation
Interventions:   Procedure: TV Annuloplasty;   Procedure: MVS Alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   German Society for Thoracic and Cardiovascular Surgery
Not yet recruiting - verified May 2016

Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Stress;   Quality of Life;   Anxiety;   Depression;   Hostility
Intervention:   Behavioral: Relaxation Response Resiliency Program
Sponsors:   Massachusetts General Hospital;   Benson-Henry Institute for Mind Body Medicine
Recruiting - verified May 2016

Vimecon CAI Trial for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)

Condition:   Atrial Fibrillation
Intervention:   Procedure: Vimecon Laser CAI percutaneous cardiac ablation
Sponsor:   Vimecon GmbH
Recruiting - verified May 2016

Circulating BDNF in Patients With Atrial Fibrillation Undergoing Catheter Ablation or Exercise Training

Condition:   Atrial Fibrillation
Interventions:   Procedure: Catheter ablation;   Behavioral: Exercise training
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting - verified May 2016

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran;   Drug: Wafrarin
Sponsor:   Boehringer Ingelheim
Not yet recruiting - verified May 2016

Patient Convenience Study (RE-SONANCE)

Conditions:   Atrial Fibrillation;   Stroke
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Predictors for Postoperative Delirium After Cardiac Surgery With Extracorporeal Circulation in Adults: a One-year, Single Center, Observational Cohort Study

Condition:   Postoperative Delirium
Intervention:   Other: no intervention
Sponsor:   University Hospital, Basel, Switzerland
Completed - verified May 2016

Patient Convenience Study

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients

Condition:   Atrial Fibrillation
Interventions:   Genetic: Pharmacogenetic anticoagulation;   Drug: Tradicional anticoagulation
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute;   Farmoquimica S.A.;   University of Sao Paulo
Recruiting - verified January 2016

Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction

Conditions:   Myocardial Infarction;   Autonomic Nervous System Diseases
Intervention:   Device: Medtronic Reveal LINQ implantable cardiac monitor
Sponsors:   Klinikum der Universitaet Muenchen;   Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK);   Medtronic Bakken Research Center
Recruiting - verified May 2016

AF Patient Preference Study

Condition:   Atrial Fibrillation
Interventions:   Drug: VKA: Warfarin (Waran);   Drug: NOAC: Rivaroxaban (Xarelto, BAY59-7939);   Drug: NOAC: Dabigatran etexilate;   Drug: NOAC: Apixaban;   Drug: NOAC: Edoxaban;   Drug: NOAC: Lixiana
Sponsor:   Bayer
Recruiting - verified May 2016

COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF

Condition:   Atrial Fibrillation
Intervention:   Drug: Colchicine group
Sponsor:   Elpen Pharmaceutical Co. Inc.
Not yet recruiting - verified May 2016

A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark

Condition:   Anticoagulation
Intervention:  
Sponsors:   Bristol-Myers Squibb;   University Hospital, Gentofte, Copenhagen
Completed - verified May 2016

Multi-Channel Esophageal ECG Signal Classification

Conditions:   Atrial Fibrillation;   Atrial Function;   Arrhythmias, Cardiac;   Atrial Premature Complexes
Intervention:  
Sponsors:   University Hospital Inselspital, Berne;   Bern University of Applied Sciences
Recruiting - verified May 2016

Anticoagulation Preference by AF Patients Study

Condition:   Atrial Fibrillation
Interventions:   Other: VKAs;   Other: NOACs including Rivaroxaban (Xarelto, BAY59-7939);   Other: Edoxaban;   Other: Apixaban;   Other: Dabigatran-etexilate
Sponsor:   Bayer
Recruiting - verified May 2016

Clinical Relevance of Microbleeds In Stroke

Conditions:   Stroke;   Atrial Fibrillation (AF);   Intracerebral Haemorrhage (ICH)
Intervention:  
Sponsor:   University College, London
Active, not recruiting - verified July 2015

Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden

Condition:   Anticoagulation
Intervention:  
Sponsor:   Bristol-Myers Squibb
Completed - verified May 2016

Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ACP-196;   Drug: ibrutinib
Sponsor:   Acerta Pharma BV
Recruiting - verified May 2016

Post-Embolic Rhythm Detection With Implantable Versus External Monitoring

Conditions:   Stroke;   Atrial Fibrillation;   Arrhythmias, Cardiac
Interventions:   Device: Medtronic Reveal LINQ;   Device: Sorin Spiderflash-t
Sponsors:   University of Alberta;   University of Calgary;   Alberta Innovates Health Solutions;   Medtronic
Recruiting - verified May 2016

A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified May 2016

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Condition:   Atrial Fibrillation
Interventions:   Drug: Warfarin;   Drug: Dabigatran Etexilate 150mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Vitamin K Supplementation in Patients on Hemodialysis

Conditions:   End Stage Renal Failure on Dialysis;   Atrial Fibrillation
Intervention:   Drug: vitamin K1
Sponsor:   University Health Network, Toronto
Recruiting - verified May 2016

Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study

Condition:   Stroke, Acute
Intervention:  
Sponsors:   University of Zurich;   Swiss National Science Foundation
Recruiting - verified May 2016

Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Condition:   Atrial Fibrillation
Interventions:   Drug: Dabigatran etexilate;   Drug: Phenprocoumon
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick

Condition:   Atrial Fibrillation
Intervention:   Device: MyDiagnostick
Sponsors:   UMC Utrecht;   Boehringer Ingelheim
Completed - verified May 2016

Left-Atrium-Appendage Occluder Register - GErmany

Conditions:   Atrial Fibrillation;   Stroke
Intervention:  
Sponsor:   Stiftung Institut fuer Herzinfarktforschung
Active, not recruiting - verified May 2016

Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"

Conditions:   Atrial Fibrillation;   Coronary Artery Disease
Interventions:   Drug: Ticagrelor+Warfarin;   Drug: Clopidogrel+Aspirin+Warfarin
Sponsors:   Genshan Ma;   Zhongda Hospital
Recruiting - verified May 2016

D-dimer Assay for the Exclusion of Intra-atrial Thrombus Risk Before Ablation of Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Other: D-dimer assay before ablation of atrial fibrillation
Sponsors:   Groupe Hospitalier de la Rochelle Ré Aunis;   Medtronic
Completed - verified May 2016

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Rivaroxaban;   Drug: Acetylsalicylic acid
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   Bayer;   Biotronik SE & Co. KG
Recruiting - verified May 2016

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation

Conditions:   Permanent Atrial Fibrillation;   Venous Thrombosis;   Pulmonary Embolism;   Anticoagulation Treatment at Least > or = to 12-month
Interventions:   Drug: Rivaroxaban;   Drug: Fluindione;   Drug: Warfarin
Sponsor:   University Hospital, Angers
Recruiting - verified May 2016

Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers

Condition:   Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Sotalol;   Drug: Placebo for BMS-919373
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2016

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Condition:   Paroxysmal Atrial Fibrillation
Interventions:   Drug: BMS-919373;   Drug: Placebo (Matching with BMS-919373)
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2016

Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only

Conditions:   Paroxysmal Atrial Fibrillation;   Persistent Atrial Fibrillation;   Out of Range Hypertension;   Signs of Sympathetic Overdrive
Intervention:   Procedure: procedure
Sponsor:   Diagram B.V.
Recruiting - verified May 2016

A Study of Caffeine on Cardiac Arrhythmias

Conditions:   Supraventricular Tachycardia (SVT);   Atrial Fibrillation
Interventions:   Drug: Caffeine;   Other: Placebo
Sponsor:   Ottawa Heart Institute Research Corporation
Active, not recruiting - verified May 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified May 2016

Autonomic Innervation and MIBG Imaging

Condition:   Atrial Fibrillation
Intervention:   Other: Iodine-123 Meta-iodobenzylguanidine
Sponsor:   Ottawa Heart Institute Research Corporation
Completed - verified May 2016

Screening for Silent Atrial Fibrillation During Influenza Vaccination

Condition:   Atrial Fibrillation
Intervention:   Device: `MyDiagnostick
Sponsors:   UMC Utrecht;   Boehringer Ingelheim
Completed - verified May 2016

Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction

Condition:   Heart Failure With Preserved Ejection Fraction (HFpEF)
Intervention:   Device: ILR implantation
Sponsors:   University Medical Center Groningen;   St. Jude Medical
Enrolling by invitation - verified May 2016

The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study

Conditions:   Atrial Fibrillation;   Alcohol
Interventions:   Drug: Ethanol;   Drug: Placebo
Sponsor:   University of California, San Francisco
Recruiting - verified May 2016

Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration

Condition:   Paroxysmal Atrial Fibrillation
Intervention:   Procedure: Pulmonary Vein Isolation
Sponsor:   University of British Columbia
Recruiting - verified May 2016

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

Condition:   Hypertrophic Cardiomyopathy
Intervention:   Other: None - this is an observational study
Sponsors:   University of Virginia;   National Heart, Lung, and Blood Institute (NHLBI);   Oxford University Hospitals NHS Trust
Recruiting - verified May 2016

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Active, not recruiting - verified May 2016

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Condition:   Atrial Fibrillation
Intervention:   Drug: Pradaxa (Dabigatran etexilate mesilate)
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia

Condition:   Atrial Fibrillation
Intervention:   Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsor:   Bayer
Completed - verified May 2016

Statin Recapture Therapy Before Coronary Artery Bypass Grafting

Condition:   Coronary Artery Disease
Interventions:   Drug: Statin Recapture Therapy;   Drug: Placebo
Sponsors:   University of Cologne;   German Federal Ministry of Education and Research
Recruiting - verified May 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Atrial Fibrillation Progression Trial

Condition:   Atrial Fibrillation
Interventions:   Device: Catheter Ablation;   Drug: Drug Treatment
Sponsor:   Biosense Webster, Inc.
Recruiting - verified May 2016

Risk Profile for Patients With Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:  
Sponsors:   I.C. Van Gelder;   Netherlands Heart Foundation
Active, not recruiting - verified May 2016

Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Condition:   Atrial Fibrillation
Intervention:   Drug: Prazaxa
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified May 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients

Condition:   Coronary Artery Disease
Intervention:   Other: biomarker samples
Sponsors:   University of Virginia;   International Anesthesia Research Society (IARS)
Completed - verified May 2016

Multi_center Study to Evaluate the Effect of N-3 Fatty Acids (OMEGA-3) on Arrhythmia Recurrence in Atrial Fibrillation

Condition:   Atrial Fibrillation
Interventions:   Drug: OMEGA-3;   Drug: Placebo soybean oil
Sponsor:   Montreal Heart Institute
Completed - verified May 2016

Predictors of Anticoagulation Control on Warfarin Therapy

Conditions:   Atrial Fibrillation;   Deep Vein Thrombosis;   Heart Valve Replacement
Intervention:  
Sponsors:   University of Pennsylvania;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified May 2016

Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure

Condition:   Atrial Fibrillation
Interventions:   Other: Upstream therapy;   Other: Conventional rhythm control
Sponsors:   I.C. Van Gelder;   The Interuniversity Cardiology Institute of the Netherlands;   Netherlands Heart Foundation;   Dutch Network for Cardiovascular Research;   Trial Coordination Center UMC Groningen;   Bayer;   Boehringer Ingelheim;   Medtronic;   Biotronik SE & Co. KG;   St. Jude Medical;   Boston Scientific Corporation;   AstraZeneca
Active, not recruiting - verified May 2016

CardioSmart Points

Log in to Check Your Balance
and Go Shopping

Learn how to earn more CardioSmart Points